Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22648858 | 0.78 | NPC1 (0.36) | HSD17B10 | |
| SCHEMBL4017830 | 0.66 | KDM4E (0.44) | KDM4EHSD17B10CYP1A2CYP2C9GAA | |
| SCHEMBL3463118 | 0.65 | CA12 (0.56) | KDM4EHSD17B10 | |
| SCHEMBL12292832 | 0.62 | ALDH1A1 (0.41) | KDM4ECYP1A2CYP2C9GAARXFP1 | |
| SCHEMBL10252488 | 0.60 | GAA (0.53) | KDM4ECYP1A2CYP2C9GAARXFP1 | |
| SCHEMBL22648857 | 0.59 | HCAR2 (0.32) | — | |
| SCHEMBL4019082 | 0.59 | KDM4E (0.64) | KDM4EHSD17B10CYP1A2CYP2C9GAA | |
| SCHEMBL4019861 | 0.59 | KDM4E (0.64) | KDM4EHSD17B10CYP1A2CYP2C9GAA | |
| SCHEMBL406753 | 0.59 | KDM4E (0.41) | KDM4EHSD17B10CYP1A2CYP2C9GAA | |
| SCHEMBL4014392 | 0.57 | TNKS2 (0.44) | KDM4EHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | CYP2A6, CYP2B6, CYP4A11 | KDM4E 1527/4885HSD17B10 237/4885CYP1A2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.